Alpha 2.0
Login Register
» Authors » Kyle Gowen

Kyle Gowen

Explore the profile of Kyle Gowen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 853
Followers 0
Related Specialties
Oncology
Molecular Biology
Pathology
Top 10 Co-Authors
Siraj M Ali
Vincent A Miller
Jeffrey S Ross
Alexa B Schrock
Sai-Hong Ignatius Ou
Philip J Stephens
Samuel J Klempner
Thomas K Lee
Julia A Elvin
Christine M Lovly
Published In
Lung Cancer
Cancer Discov
Oncologist
Nat Genet
J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy
Chudnovsky Y, Kumar R, Schrock A, Connelly C, Gowen K, Frampton G, et al.
JCO Precis Oncol . 2022 Feb; 1:1-9. PMID: 35172500
No abstract available.
2.
Recent kuru-induced female gene flow disrupted the coevolution of genes and languages in the Papua New Guinea highlands
Li M, DeRosa K, Mann H, Spathis R, Roome A, Castellanos D, et al.
Am J Phys Anthropol . 2020 Mar; 172(1):87-98. PMID: 32150286
Objectives: The island of New Guinea was settled by modern human over 50,000 years ago, and is currently characterized by a complex landscape and contains one-seventh of the world's languages....
3.
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples
Trabucco S, Gowen K, Maund S, Sanford E, Fabrizio D, Hall M, et al.
J Mol Diagn . 2019 Aug; 21(6):1053-1066. PMID: 31445211
Microsatellite instability (MSI) is an important biomarker for predicting response to immune checkpoint inhibitor therapy, as emphasized by the recent checkpoint inhibitor approval for MSI-high (MSI-H) solid tumors. Herein, we...
4.
Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion
Tsou T, Gowen K, Ali S, Miller V, Schrock A, Lovly C, et al.
J Thorac Oncol . 2019 Jan; 14(2):e29-e30. PMID: 30683295
No abstract available.
5.
Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation
Klempner S, Gowen K, Lee T, Zhu V, Schrock A, Miller V, et al.
Lung Cancer . 2018 Oct; 124:86-89. PMID: 30268485
Non-small cell lung cancer (NSCLC) has emerged as a paradigm for clinical application of precision medicine as optimal therapy is commonly chosen based on genomic biomarkers identified in a patient's...
6.
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
Fabrizio D, George Jr T, Dunne R, Frampton G, Sun J, Gowen K, et al.
J Gastrointest Oncol . 2018 Aug; 9(4):610-617. PMID: 30151257
Background: The clinical application of targeting checkpoint inhibitors in colorectal cancer (CRC) has largely focused on a subset of microsatellite instable (MSI-high) patients. However, the proposed genotype that sensitizes these...
7.
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Lin J, Zhu V, Yoda S, Yeap B, Schrock A, Dagogo-Jack I, et al.
J Clin Oncol . 2018 Jan; 36(12):1199-1206. PMID: 29373100
Purpose Advanced anaplastic lymphoma kinase ( ALK) fusion-positive non-small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs). However, clinical outcomes in these patients vary, and the...
8.
Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System
Gupta S, Albertson D, Gaston D, Heilbrun M, Agarwal N, Boucher K, et al.
Clin Genitourin Cancer . 2017 Oct; 16(2):e373-e382. PMID: 28974397
Purpose: Tumor genomic profiling helps direct therapy for advanced urothelial carcinoma (UC). In the course of clinical care, we encountered a patient with a complete loss of SMARCB1 (switch/sucrose nonfermentable-related...
9.
De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma
Carney B, Rangachari D, VanderLaan P, Gowen K, Schrock A, Ali S, et al.
Lung Cancer . 2017 Sep; 114:108-110. PMID: 28870636
No abstract available.
10.
A recurrent endometrial stromal sarcoma harbors the novel fusion
Allen A, Ali S, Gowen K, Elvin J, Pejovic T
Gynecol Oncol Rep . 2017 Mar; 20:51-53. PMID: 28331900
•Genomic alterations may improve diagnostic certainty and subsequent treatment of endometrial stromal sarcoma.•Novel JAZF1-BCORL1 mutation was identified.•Targeted therapeutics to down-stream targets may improve survival benefit in these patients.